Cuba is experiencing its most severe arboviral disease crisis in decades, with widespread circulation of dengue virus serotypes 3 and 4, chikungunya, and Oropouche across several provinces. Substantial underreporting is suggested.
- Chikungunya: As of week 50: more than 45’000 cases (1’569 confirmed); incidence 415/1’000. Transmission remains high.
- Dengue: As of week 50: more than 28’000 cases; incidence 264/1’000.
Cuba is classified as a country experiencing a chikungunya outbreak.
Prevention: Optimal mosquito protection 24/7, also in cities (also against other mosquito-borne diseases).
Vaccination against chikungunya is recommended.
Two chikungunya vaccines have been licensed in Europe: Vimkunya® (virus-like particle vaccine, licensed in 2025) and Ixchiq® (live-attenuated vaccine, licensed in July 2024). Neither vaccine is licensed in Switzerland. Consultation with a travel or tropical medicine specialist is advised, see also ECTM vaccination recommendation against chikungunya.
For vaccination against dengue: see ECTM statement.